| B4 androgen ablation: attacking the prostate cancer stem cell. | |
| | |
MedLine Citation:
|
PMID: 23348735 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
There is increasing evidence that prostate cancers in rodent models and in men contain a cellular subpopulation that displays stem cell properties. These prostate cancer stem cells (PCSCs) lack androgen receptor expression and are increased in castration-resistant disease. In this issue of the JCI, a study from Yoshioka et al. demonstrates that PCSCs are regulated by a pathway in which α6β4 integrin amplifies signaling through ErbB2 and c-Met receptors. Targeting this pathway provides a novel therapeutic strategy for hormone refractory prostate cancer. |
| | |
Authors:
|
Max S Wicha |
Related Documents
:
|
23160385 - Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency doe... 18566225 - Stat3 inhibition in prostate and pancreatic cancer lines by stat3 binding sequence olig... 20660965 - Circulating apoptotic markers in the management of non-small cell lung cancer. 23276935 - Cd133+ cancer stem cells in lung cancer . 16246185 - Somatic mutations of mitochondrial dna in digestive tract cancers. 6841615 - Utility of mmpi indices of schizophrenia with adolescents. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-25 |
Journal Detail:
|
Title: The Journal of clinical investigation Volume: - ISSN: 1558-8238 ISO Abbreviation: J. Clin. Invest. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7802877 Medline TA: J Clin Invest Country: - |
Other Details:
|
Languages: ENG Pagination: 1-3 Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?
Next Document: Why stress is BAD for cancer patients.